<code id='3051A93375'></code><style id='3051A93375'></style>
    • <acronym id='3051A93375'></acronym>
      <center id='3051A93375'><center id='3051A93375'><tfoot id='3051A93375'></tfoot></center><abbr id='3051A93375'><dir id='3051A93375'><tfoot id='3051A93375'></tfoot><noframes id='3051A93375'>

    • <optgroup id='3051A93375'><strike id='3051A93375'><sup id='3051A93375'></sup></strike><code id='3051A93375'></code></optgroup>
        1. <b id='3051A93375'><label id='3051A93375'><select id='3051A93375'><dt id='3051A93375'><span id='3051A93375'></span></dt></select></label></b><u id='3051A93375'></u>
          <i id='3051A93375'><strike id='3051A93375'><tt id='3051A93375'><pre id='3051A93375'></pre></tt></strike></i>

          knowledge

          knowledge

          author:hotspot    Page View:94736
          Adobe

          UnitedHealth Group’s Optum subsidiary saw a lower operating margin in the second quarter due to more seniors getting care, a spike in demand for behavioral health services, and an influx of members with higher health needs.

          “Those three elements, the senior trend piece, the behavioral piece, and then the effects of the strong growth is really what explains what’s going on,” UnitedHealth Group CEO Andrew Witty said on the company’s earnings call on Friday. “We’ll continue to lean into that growth very assertively.”

          advertisement

          Minnetonka, Minn.-based UnitedHealth Group’s Optum segment, which includes its provider arm, its pharmacy benefit manager, and its data and technology arm, reported an operating margin of 6.6% in the quarter ended June 30, compared with 7.3% in the prior-year period. Leaders said the decline was within its provider arm, Optum Health.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          J&J to emphasize cancer drugs, stop much of its vaccine research
          J&J to emphasize cancer drugs, stop much of its vaccine research

          DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm

          read more
          In Memoriam: Notable people who died in 2023
          In Memoriam: Notable people who died in 2023

          1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

          read more

          Mayo Clinic plans $5B tech

          ArenderingshowstheplannedexpansionofMayoClinic'sflagshipcampus.MayoClinicMayoClinicwillspend$5billio